XXXX therapy as pre-operative adjunct of non-functional pituitary macroadenomas.

@entity1 @entity2847 @entity2013 @entity5 @entity1504 @entity1188 @entity977 @entity652
Although @entity2847 administration produces reduction in size of @entity2013 , its effect upon non-functional @entity977 is still uncertain. Nine @entity1 with macroadenomas, 2 of them with @entity2013 and 7 with @entity5 , received @entity2847 prior to transsphenoidal surgery. Size @entity5 mass was assessed by computerized tomography and by visual field examination before and following @entity2847 treatment. There were no signs of size diminution or pathological changes in the non-functional @entity652 treated pharmacologically during 15 to 360 days. Both @entity1 with @entity2013 had radiological evidence of size reduction and morphological changes on microscopic examination. These 2 @entity1 had @entity5 with prolactin granules (immunocytochemistry) and @entity652 cells showed reduced cytoplasmatic, nuclear and nucleolar areas. Neither @entity1504 , cell necrosis, nor @entity1188 was observed by electron microscopy. @entity1 with @entity5 as determined by immunocytochemistry and hormone production did not benefit from @entity2847 . The suggestion that @entity2847 can be used as primary treatment for non-functional @entity5 is not supported by the present study. Conversely, in cases of @entity2013 , @entity2847 is a useful pre-operative adjunct when surgery is planned and for those @entity1 in whom a surgical cure is considered difficult owing to the @entity5 size.
